On May 14, 2024, Paragon Therapeutics Announced A License Agreement Granting Spyre Therapeutics An Exclusive License To Certain Antibodies And Products Targeting Α4SS7 Integrin And Tl1A, Paragon Will Up To $22M In Milestone Payments-8K
On May 14, 2024, Paragon Therapeutics Announced A License Agreement Granting Spyre Therapeutics An Exclusive License To Certain Antibodies And Products Targeting Α4SS7 Integrin And Tl1A, Paragon Will Up To $22M In Milestone Payments-8K
2024年5月14日，Paragon Therapeutics宣布了一项许可协议，授予Spyre Therapeutics对某些针对Α4SS7整合素和Tl1A的抗体和产品的独家许可，Paragon将获得高达2200万美元的里程碑付款-8K
- Paragon will provide the Company with an exclusive license to its patents covering the related antibody, the method of use and its method of manufacture.
- Paragon will not conduct any new campaigns that generate anti-α4ß7 or anti-TL1A monospecific antibodies for at least 5 years.
- The Company will pay Paragon a low single-digit percentage royalty for single antibody products and a mid single-digit percentage royalty for products containing more than one antibody from Paragon.
- There is a royalty step-down of 1/3rd if there is no Paragon patent in effect during the royalty term.
- The royalty term ends on the later of (i) the last-to-expire licensed patent or Company patent directed to a derived antibody or (ii) 12 years from the date of first sale of a Company product.
- Agreement may be terminated on 60 days' notice by the Company; on material breach without cure; and to the extent permitted by law, on a party's insolvency or bankruptcy.
- With respect to the SPY002 License Agreement only, on a product by product basis, the Company will pay Paragon sublicensing fees of up to approximately $20 million upon the achievement of mostly commercial milestones.
- Paragon将向公司提供其专利的独家许可，该专利涵盖相关抗体、使用方法及其制造方法。
- Paragon在至少5年内不会开展任何产生抗α4β7或抗TL1A单特异性抗体的新活动。
- 该公司将为单一抗体产品向Paragon支付较低的个位数百分比的特许权使用费，对于含有来自Paragon的一种以上抗体的产品，将支付中等个位数百分比的特许权使用费。
- 如果在特许权使用费期内没有有效的Paragon专利，则特许权使用费将降低三分之一。
- 特许权使用费期限于 (i) 针对衍生抗体的最后到期的许可专利或公司专利，或 (ii) 自公司产品首次销售之日起12年，以较低者为准。
- 协议可以在公司提前60天发出通知后终止；如果发生重大违约而无法补救；在法律允许的范围内，当事方破产或破产。
- 仅针对 SPY002 许可协议，在实现主要商业里程碑后，公司将逐个产品向Paragon支付高达约2,000万美元的再许可费。